Management
Dean J. Welsch, PhD
Chief Executive Officer (interim)/Chief Scientific Officer
Dr. Welsch has over 30 years of experience in pharmaceutical research and development, including having led programs in oncology, inflammation, allergy & respiratory, and cardiovascular therapeutic areas. His expertise includes aspects of drug development from identification of novel drug targets through completion of Phase IIa clinical proof-of-concept studies. Prior to joining ImmunoMet Therapeutics in 2020, Dr. Welsch served as Vice President of Biology at Peloton Therapeutics and earlier as Executive Director of Translation Sciences at BioMed Valley Discoveries, where he led their first-in-class ERK inhibitor program. His career includes 20 years with Pfizer and legacy companies where he had both scientific and management leadership responsibilities.
Dr. Welsch received a BS in Chemistry from Hope College, a PhD in Biochemistry from the University of Minnesota in the lab of Dr. G. Nelsestuen, and completed his post-doctoral training with Dr. P. Friedman at Merck Research Labs. He has co-authored more than 35 peer-reviewed publications and is a co-inventor on 7 patents.
Dr. Welsch received a BS in Chemistry from Hope College, a PhD in Biochemistry from the University of Minnesota in the lab of Dr. G. Nelsestuen, and completed his post-doctoral training with Dr. P. Friedman at Merck Research Labs. He has co-authored more than 35 peer-reviewed publications and is a co-inventor on 7 patents.